胶质母细胞瘤术中放疗的国际汇总分析
该国际汇总分析纳入德国、中国和秘鲁五中心51例新诊断胶质母细胞瘤患者,在肿瘤切除后予低能X线单次术中放疗(10-40 Gy),随后行标准辅助放化疗。中位随访18.0个月,中位总生存18.0个月,1/2/3年总生存率分别为79.5%、38.7%、25.6%;仅35.3%首次进展为局部,3级放射性坏死发生率17.6%,无4级毒性及治疗相关死亡。
要点
- 低能X线术中放疗联合标准治疗的中位OS为18.0个月。
- 首次进展为局部者仅35.3%,提示局部控制可能获益。
- 3级放射性坏死发生率17.6%,无4级毒性及治疗相关死亡。
核心结论
- 与历史数据相比,该汇总分析提示低能X线术中放疗治疗新诊断胶质母细胞瘤可能提高疗效和安全性。
- 需前瞻性数据证实上述发现。
研究设计与样本
- 国际多中心汇总分析,纳入德国、中国和秘鲁五中心共51例胶质母细胞瘤患者。
- 所有患者接受肿瘤切除后单次低能X线术中放疗(10-40 Gy,处方至施源器表面),随后行标准辅助放化疗和维持化疗。
主要发现
- 中位年龄55岁(范围16-75),中位Karnofsky功能状态评分80(范围20-100)。
- 中位随访18.0个月(范围2-42.4),中位总生存18.0个月(95%CI: 14.7-21.3)。
- 中位无进展生存11.4个月(95%CI: 7.58-15.22),中位局部无进展生存16个月(95%CI: 10.21-21.8),中位远处无进展生存30.0个月(95%CI: 18.59-41.41)。
- 1年、2年、3年总生存率分别为79.5%、38.7%、25.6%;无进展生存率分别为46.2%、29.4%、5.9%;局部无进展生存率分别为60.9%、37.9%、12.6%;远处无进展生存率分别为76.7%、65.0%、39.0%。
- 首次进展为局部者占35.3%;1级放射性坏死发生率7.8%,3级17.6%,无4级毒性,无治疗相关死亡。
关键数值与推荐
- 术中放疗剂量为10-40 Gy,处方至施源器表面,使用低能X线。
- 局部无进展生存定义为出现距瘤腔边界≤1 cm的新病灶,远处无进展生存定义为病灶>1 cm。
- 放射性坏死按Common Terminology Criteria for Adverse Events Version 5.0分级。
临床怎么用
- 对于新诊断胶质母细胞瘤,在肿瘤切除后联合低能X线术中放疗可作为标准治疗基础上的强化策略,但需前瞻性研究证实。
- 术中放疗后应继续标准辅助放化疗和维持化疗。
- 需关注放射性坏死,按CTCAE v5.0分级监测,该分析中3级发生率为17.6%。
局限性
- 为回顾性汇总分析,样本量51例,证据级别有限。
- 与历史数据比较,非随机对照,存在混杂偏倚可能。
- 中位随访18.0个月,长期生存数据尚不成熟。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To report the results of the first international pooled analysis of patients with glioblastoma treated with intraoperative radiotherapy (IORT) in addition to standard of care therapy. METHODS: Data from 51 patients treated at five centers in Germany, China and Peru were analyzed. All patients underwent tumor resection followed by a single application of IORT (10-40 Gy, prescribed to the applicator surface) with low-energy X-rays. Thereafter, standard adjuvant radiochemotherapy and maintenance chemotherapy were applied. Factors of interest were overall survival (OS), progression-free survival (PFS), local PFS (L-PFS; defined as appearance of new lesions ≤1 cm to the cavity border) and distant PFS (D-PFS; lesions >1 cm). The same endpoints were estimated at 1-, 2- and 3-years using the Kaplan-Meier method. Additionally, rates and severity (as per Common Terminology Criteria for Adverse Events Version 5.0) of radionecrosis (RN) were analyzed. RESULTS: The median age was 55 years (range: 16-75) and the median Karnofsky Performance Status was 80 (20-100). At a median follow-up of 18.0 months (2-42.4), the median OS, PFS, L-PFS and D-PFS were 18.0 months (95% CI: 14.7-21.3), 11.4 months (95%CI: 7.58-15.22), 16 months (95%CI: 10.21-21.8) and 30.0 months (95%CI: 18.59 - 41.41), respectively. The estimated 1-, 2- and 3-year OS, PFS, L-PFS and D-PFS were 79.5%, 38.7% and 25.6%; 46.2%, 29.4%, and 5.9%; 60.9, 37.9%, and 12.6%; and 76.7%, 65.0%, and 39.0% respectively. First progression occurred locally in only 35.3% of cases. Grade 1 RN was detected in 7.8% and grade 3 in 17.6% of the patients. No grade 4 toxicity was reported and no treatment-related deaths occurred. CONCLUSION: Compared to historical data, this pooled analysis suggests improved efficacy and safety of IORT with low-energy X-rays for newly diagnosed glioblastoma. Prospective data is warranted to confirm these findings.
引用
- Sarria GR, Sperk E, Han X, et al. Intraoperative radiotherapy for glioblastoma: an international pooled analysis. Radiother Oncol. 2019. PMID: 31629553. doi:10.1016/j.radonc.2019.09.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。